Really can’t expect a better result than that for the first year of IPO. Strong gross margins offer high likelihood of reaching profit if sales growth continue as expected. I think the range of products launched during the year will underpin strong growth in FY’23. It’s an impressive range and the pace that BIO rolled out it’s distribution channels despite the challenges of COVID and supply chain constraints is even more impressive. Looks like we are all set for a great year ahead. Well done BIO!
Ann: Preliminary Final Report, page-2
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.04M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 33.5¢ | 31.5¢ | $80.66K | 253.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37657 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 41259 | 2 |
View Market Depth
| Last trade - 11.40am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
32.5¢ |
Change
0.000 ( 1.52 %) |
||||
| Open | High | Low | Volume | ||
| 32.5¢ | 32.5¢ | 31.5¢ | 65352 | ||
| Last updated 11.58am 04/06/2024 ? | |||||
| BIO (ASX) Chart |